Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.

Blood - 5 Feb 2026

Semba Yuichiro, Yamauchi Takuji, Bauer Daniel E, Ogawa Seishi, Akashi Koichi, Maeda Takahiro

Abstract excerpt

ABSTRACT: Acute myeloid leukemia (AML) with TP53 mutations is almost universally refractory to chemotherapy, molecular-targeted therapies, and hematopoietic stem cell transplantation, leading to dismal clinical outcomes. The lack of effective treatments underscores the urgent need for novel therapeutic strategies. Using genome-wide CRISPR/Cas9 dropout screens in isogenic Trp53-wild-type (WT) and Trp53-knockout...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Gene Expression Regulation, Leukemic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Karyopherins

Share to Leukemia, Myeloid, Acute

Share to Mice, Knockout

Share to Receptors, Cytoplasmic and Nuclear

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41160778
DOI: 10.1182/blood.2025028918

Genes

TP53
XPO7
NPAT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.PMID 41160778Read ↗

ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia.Semantic proximity Read ↗

Clinical and Molecular Characterization of p53-Mutated Acute Myeloid LeukemiaSemantic proximity Read ↗

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.Semantic proximity Read ↗

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.Semantic proximity Read ↗

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.Semantic proximity Read ↗

Wild-Type p53 Overexpression in NPM1-Mutated AML: Potential Implications for Disease Biology and Therapy ResponseSemantic proximity Read ↗

The role of TP53 in acute myeloid leukemia: Challenges and opportunitiesSemantic proximity Read ↗

XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignanciesSemantic proximity Read ↗

USP7 as part of non-canonical PRC1.1 is a druggable target in leukemiaSemantic proximity Read ↗

Deciphering <i>TP53</i> mutant Cancer Evolution with Single-Cell Multi-OmicsSemantic proximity Read ↗

A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1Semantic proximity Read ↗

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.